HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

Published:2001-09 Issue:1 Volume:69 Page:53-63
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Konecny Gottfried,Fritz Manuel,Untch Michael,Lebeau Annette,Felber Margrit,Lude Sandra,Beryt Malgorzata,Hepp Hermann,Slamon Dennis,Pegram Mark

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.springerlink.com/index/pdf/10.1023/A:1012226006395

Reference28 articles.

1. Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res 52: 65-77, 1998

2. Ravdin P: The use of HER2 testing in the management of breast cancer. Semin Oncol 27(5 Suppl 9): 33-42, 2000

3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulirich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification on HER-2/neu oncogene. Science 235: 177-182, 1987

4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989

5. Carraway KL III, Cantley LC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5-8, 1994

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A careful reassessment of anthracycline use in curable breast cancer;npj Breast Cancer;2021-10-08

2. ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab;BMC Cancer;2015-09-07

3. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study;Journal of Cancer Research and Clinical Oncology;2015-08-25

4. Benefit from anthracyclines in relation to biological profiles in early breast cancer;Breast Cancer Research and Treatment;2014-01-01

5. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer;Breast Cancer Research and Treatment;2009-10-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3